NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.
about
Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formationTrypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccineSerum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy.Linear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunityMelanoma: tumor microenvironment and new treatments.Effective inhibition of melanoma tumorigenesis and growth via a new complex vaccine based on NY-ESO-1-alum-polysaccharide-HH2.A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigen.A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma.ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.Trypanosoma cruzi as an effective cancer antigen delivery vector.ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway.ISCOM-based vaccines: the second decade.HLA class I transgenic mice: development, utilisation and improvement.Enhancement of dendritic cells as vaccines for cancerPresentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectorsRecombinant Lactobacillus plantarum induces immune responses to cancer testis antigen NY-ESO-1 and maturation of dendritic cells.De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1.Promises and limitations of murine models in the development of anticancer T-cell vaccines.ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.Dendritic cell-based cancer vaccination: quo vadis?Promising particle-based vaccines in cancer therapy.Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant.Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment.Melanoma vaccines: developments over the past 10 years.Applications of nanotechnology for immunology.Evolving role of tumor antigens for future melanoma therapies.An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma.The Tat-conjugated N-terminal region of mucin antigen 1 (MUC1) induces protective immunity against MUC1-expressing tumours.A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant.Co-delivery of human cancer-testis antigens with adjuvant in protein nanoparticles induces higher cell-mediated immune responses.Blockade of CTLA-4 promotes the development of effector CD8+ T lymphocytes and the therapeutic effect of vaccination with an attenuated protozoan expressing NY-ESO-1.Expression and clinical significance of placenta-specific 1 in pancreatic ductal adenocarcinoma.
P2860
Q28393754-A8DE0DE8-DF32-4484-894C-AF43855CC6B6Q28483146-E5BA39EF-5162-4C0F-9B29-A4E6A07B16D0Q31138173-FE600729-FFB2-4E97-A7DF-05D9CB0C6262Q33614657-79439350-8DE0-4815-99BA-9852FD0D8B0CQ33675676-388312FF-94B0-4392-B0CB-C8C13484F07DQ33994533-6C714E00-A0B3-42E1-8CCB-527EDEDA2132Q34412732-C50FE6A2-9B05-4566-8120-CB58C8CBC075Q34461203-E1AFB812-ABAB-4C53-ADDC-08C6D7BFDB7FQ34848159-E413AB0B-2250-413D-B9E3-029299CCAC4BQ35621200-367539A2-613B-4D62-B627-74ED37AEA208Q36001701-D9BEAA9F-0E5D-4D26-ACEC-F915BEB5B1F2Q36062124-0003F47C-A94E-4BB3-9B48-594C12260901Q36194073-492D5DB7-9CC0-4FE8-9080-4DDBF455B5FCQ36209210-4A79A0E8-9201-4F5C-A875-ACDF9BEAB0B8Q36327106-6A69118B-1019-4457-B3CA-E28F12CAFC99Q36389054-EE45BF5E-1B81-4B87-9097-D5B23B3731C6Q36459332-BDD11DA2-97C1-423A-8F13-22A29662C6BEQ36471827-2C9F0FC1-D17C-4A34-910B-104A153A4E91Q36684482-7E541A1A-2F32-4666-9544-57D6001F2B0DQ36968280-204ED914-FAAB-4028-9F53-96B07EFD9217Q37259624-3C6681F6-2DCB-4EC0-8D86-4B2249ED2341Q37259642-72CC6303-1F18-4EE2-B5DA-0E47E2F3665FQ37452772-2B1B859E-EF11-4B62-88A0-EC9FE3CB5243Q37737327-7BC32C91-73A0-4E27-A574-0E4A9146C82CQ37892595-0FF81684-2580-4EFB-A1E8-F893F5E79422Q38123937-498634EF-9B62-466A-9AF9-467B6E14A2E5Q38232855-B09E3B28-2133-4B09-A19A-0D99D89FD737Q39703281-CC7A0A8F-2EE7-40C6-B53E-8174364F6533Q39802340-E32A9865-9B52-422C-90C4-AAD27DC4442AQ42505471-59ACDC46-BBCD-4089-9589-D0D85D2B9701Q46193557-D46A2F52-285E-45B3-A90A-89C32A37E54CQ50770388-E25207EB-2470-4DD3-9443-CBC4EBE1219CQ50942820-BEEA804E-88B8-40D7-9859-A57211269EAC
P2860
NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
NY-ESO-1 protein formulated in ...... tion against NY-ESO-1+ tumors.
@en
type
label
NY-ESO-1 protein formulated in ...... tion against NY-ESO-1+ tumors.
@en
prefLabel
NY-ESO-1 protein formulated in ...... tion against NY-ESO-1+ tumors.
@en
P2093
P1476
NY-ESO-1 protein formulated in ...... tion against NY-ESO-1+ tumors.
@en
P2093
Anders Sjölander
Debbie P Drane
Eugene Maraskovsky
Francois A Lemonnier
Jonathan Cebon
Luis Mateo
Martin J Pearse
Max Schnurr
Qiyuan Chen
Sigrid Sjölander
P304
P356
10.1158/1078-0432.CCR-03-0245
P407
P577
2004-04-01T00:00:00Z